MLM Share Price

Open 0.46 Change Price %
High 0.48 1 Day -0.02 -4.35
Low 0.43 1 Week 0.01 2.33
Close 0.44 1 Month 0.00 0.00
Volume 18598832 1 Year 0.08 22.22
52 Week High 0.64
52 Week Low 0.22
MLM Important Levels
Resistance 2 0.49
Resistance 1 0.47
Pivot 0.45
Support 1 0.41
Support 2 0.39
BIT Italy Most Active Stocks
UCG 2.75 4.96%
SPM 0.51 4.08%
SPM 0.51 4.08%
PMI 0.36 0.00%
PMI 0.36 0.00%
ISP 2.43 0.41%
TIT 0.84 -1.18%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
CLE 0.43 10.26%
CLE 0.43 10.26%
FUL 1.78 9.88%
FUL 1.78 9.88%
NRST 3.53 8.95%
MIC 4.31 7.75%
More..
BIT Italy Top Losers Stocks
PR 0.08 -11.11%
PR 0.08 -11.11%
SPMR 5.41 -9.83%
IIN 0.23 -8.00%
IIN 0.23 -8.00%
IIN 0.23 -8.00%
RIC 0.19 -5.00%
RIC 0.19 -5.00%
RIC 0.19 -5.00%
RIC 0.19 -5.00%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 4
As on 17th Jan 2017 MLM Share Price closed @ 0.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.38 & Strong Buy for SHORT-TERM with Stoploss of 0.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.